Multiple patient samples of an analyte improve detection of changes in clinical status

Jan 06, 2010

Clinicians rely on laboratory tests to monitor the progression or remission of disease, or to identify pathologic alterations in physiology that may precede clinical events. Monitoring quantitative laboratory results represents a crucial component in the assessment of response to therapy. Researchers at Boston University School of Medicine (BUSM) have developed a mathematical methodology to reduce the effect of biologic variation on the difference necessary to detect changes in clinical status. The findings, which appear in the January issue of Archives of Pathology & Laboratory Medicine, may lead to better patient predictions at a lower cost.

When comparing results over time, biologic variation must be statistically incorporated into the evaluation of laboratory results to identify a physiologic change. Traditional methods compare the difference in two values with the standard deviation (SD) of the biologic variation to indicate whether a ''true'' physiologic change has occurred.

Using a mathematical model, the BUSM researchers evaluated multiple paired sets of patient data, rather than a single pair, and found a substantial decrease in the difference between values necessary to achieve a given confidence interval, thereby improving the sensitivity of the evaluation.

"Our results show that we can obtain better predictions with what will happen with a patient, such as return to the hospital because of heart failure for example, at a lower cost," said study author Martin Kroll, MD, a professor of pathology and laboratory at BUSM. "The study shows that the practice of using multiple patient samples results in enhanced power to detect true changes in patient physiology," he added.

According to the researcher this approach has the potential to contribute to the personalization of health care delivery by redefining common thresholds in clinical patient management. "The decision to treat a patient with a more aggressive therapeutic regimen may be reconsidered when a test can show that a small but highly statistically significant change has taken place," explained Kroll. "Such a result may lead to the postponement of switching to a new therapeutic regimen until the next testing time, where the initial small but significant change in test values has grown to be both statistically and clinically relevant." Thus, a small difference in results may herald a true physiologic transition, a message that might easily be overlooked with older techniques.

The researcher believes testing multiple samples has the potential to fundamentally alter the way in which laboratory medicine is practiced. Greater research into the feasibility and cost of multiple testing paradigms in the clinical setting is recommended.

Explore further: Simulation-based training improves endoscopy execution

More information: www.archivesofpathology.org

Provided by Boston University Medical Center

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New treatment model for HIV

Jul 13, 2007

Treatment of HIV patients must balance the need to suppress viral replication against the harmful side effects and significant cost to the patient of antiretroviral therapy.

Model against unnecessary use of antibiotics

Oct 15, 2008

Patients in intensive care units are often administered antibiotics against ventilator-associated pneumonia, "to be on the safe side." Dutch researcher Stefan Visscher has developed a model that can quickly establish whether ...

Recommended for you

Simulation-based training improves endoscopy execution

Oct 18, 2014

(HealthDay)—Simulation-based training (SBT) improves clinicians' performance of gastrointestinal endoscopy in both test settings and clinical practice, according to research published in the October issue ...

Data sharing in pharmaceutical industry shows progress

Oct 16, 2014

To enhance the transparency of clinical trials for new drugs, a number of pharmaceutical firms have begun sharing data with investigators outside their own companies. Brian L. Strom, chancellor of Rutgers Biomedical and Health ...

Swiss drug maker Roche posts flat 3Q sales

Oct 16, 2014

(AP)—Swiss drugmaker Roche Holding AG has reported "stable" or flat sales for the first nine months of 2013 but says the results show strong demand for its cancer drugs and emerging new products.

User comments : 0